Skip to Content
Global News Select

Boston Scientific 1Q Profit, Sales Rise

By Dave Sebastian


Boston Scientific Corp. said its profit rose for the first quarter as sales increased, including a 10% growth in its cardiovascular sales.

The Marlborough, Mass.-based medical-products company Wednesday posted net income of $341 million, compared with $11 million in the prior year. Earnings were 23 cents a share, compared with a penny a share in the year-ago period.

Adjusted earnings were 37 cents a share. Analysts polled by FactSet were looking for 31 cents a share. The company had guided earnings of 5 cents a share to 11 cents a share, and 28 cents a share to 34 cents a share on an adjusted basis.

Net sales rose 8.2% to $2.75 billion, ahead of its guidance of a flat to 6% growth. Analysts were looking for $2.62 billion.


Write to Dave Sebastian at


(END) Dow Jones Newswires

April 28, 2021 06:58 ET (10:58 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.